1397 related articles for article (PubMed ID: 26685004)
21. Sputum hyaluronan and versican in severe eosinophilic asthma.
Ayars AG; Altman LC; Potter-Perigo S; Radford K; Wight TN; Nair P
Int Arch Allergy Immunol; 2013; 161(1):65-73. PubMed ID: 23257685
[TBL] [Abstract][Full Text] [Related]
22. Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.
Latorre M; Bacci E; Seccia V; Bartoli ML; Cardini C; Cianchetti S; Cristofani L; Di Franco A; Miccoli M; Puxeddu I; Celi A; Paggiaro P
Ther Adv Respir Dis; 2020; 14():1753466620965151. PubMed ID: 33263506
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial.
Neighbour H; Boulet LP; Lemiere C; Sehmi R; Leigh R; Sousa AR; Martin J; Dallow N; Gilbert J; Allen A; Hall D; Nair P
Clin Exp Allergy; 2014 Apr; 44(4):508-16. PubMed ID: 24286456
[TBL] [Abstract][Full Text] [Related]
24. Responsiveness to oral prednisolone in severe asthma is related to the degree of eosinophilic airway inflammation.
Sousa AR; Marshall RP; Warnock LC; Bolton S; Hastie A; Symon F; Hargadon B; Marshall H; Richardson M; Brightling CE; Haldar P; Milone R; Chalk P; Williamson R; Panettieri R; Knowles R; Bleecker ER; Wardlaw AJ
Clin Exp Allergy; 2017 Jul; 47(7):890-899. PubMed ID: 28493293
[TBL] [Abstract][Full Text] [Related]
25. Eosinophil Lineage-Committed Progenitors as a Therapeutic Target for Asthma.
Salter BM; Ju X; Sehmi R
Cells; 2021 Feb; 10(2):. PubMed ID: 33669458
[TBL] [Abstract][Full Text] [Related]
26. The association between airway eosinophilic inflammation and IL-33 in stable non-atopic COPD.
Tworek D; Majewski S; Szewczyk K; Kiszałkiewicz J; Kurmanowska Z; Górski P; Brzeziańska-Lasota E; Kuna P; Antczak A
Respir Res; 2018 Jun; 19(1):108. PubMed ID: 29859068
[TBL] [Abstract][Full Text] [Related]
27. Eosinophilic Endotype of Asthma.
Aleman F; Lim HF; Nair P
Immunol Allergy Clin North Am; 2016 Aug; 36(3):559-68. PubMed ID: 27401626
[TBL] [Abstract][Full Text] [Related]
28. Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma.
Jayaram L; Duong M; Pizzichini MM; Pizzichini E; Kamada D; Efthimiadis A; Hargreave FE
Eur Respir J; 2005 Jan; 25(1):41-6. PubMed ID: 15640321
[TBL] [Abstract][Full Text] [Related]
29. Sputum basophils are increased in eosinophilic asthma compared with non-eosinophilic asthma phenotypes.
Brooks CR; van Dalen CJ; Hermans IF; Gibson PG; Simpson JL; Douwes J
Allergy; 2017 Oct; 72(10):1583-1586. PubMed ID: 28426171
[TBL] [Abstract][Full Text] [Related]
30. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.
Flood-Page P; Swenson C; Faiferman I; Matthews J; Williams M; Brannick L; Robinson D; Wenzel S; Busse W; Hansel TT; Barnes NC;
Am J Respir Crit Care Med; 2007 Dec; 176(11):1062-71. PubMed ID: 17872493
[TBL] [Abstract][Full Text] [Related]
31. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
Magnan A; Bourdin A; Prazma CM; Albers FC; Price RG; Yancey SW; Ortega H
Allergy; 2016 Sep; 71(9):1335-44. PubMed ID: 27087007
[TBL] [Abstract][Full Text] [Related]
32. Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.
Kelly EA; Esnault S; Liu LY; Evans MD; Johansson MW; Mathur S; Mosher DF; Denlinger LC; Jarjour NN
Am J Respir Crit Care Med; 2017 Dec; 196(11):1385-1395. PubMed ID: 28862877
[TBL] [Abstract][Full Text] [Related]
33. Mepolizumab: First Global Approval.
Keating GM
Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
[TBL] [Abstract][Full Text] [Related]
34. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
Gupta A; Ikeda M; Geng B; Azmi J; Price RG; Bradford ES; Yancey SW; Steinfeld J
J Allergy Clin Immunol; 2019 Nov; 144(5):1336-1342.e7. PubMed ID: 31425781
[TBL] [Abstract][Full Text] [Related]
35. Mepolizumab for the treatment of severe eosinophilic asthma.
Poulakos MN; Cargill SM; Waineo MF; Wolford AL
Am J Health Syst Pharm; 2017 Jul; 74(13):963-969. PubMed ID: 28645995
[TBL] [Abstract][Full Text] [Related]
36. Anti-IL-5 in Mild Asthma Alters Rhinovirus-induced Macrophage, B-Cell, and Neutrophil Responses (MATERIAL). A Placebo-controlled, Double-Blind Study.
Sabogal Piñeros YS; Bal SM; van de Pol MA; Dierdorp BS; Dekker T; Dijkhuis A; Brinkman P; van der Sluijs KF; Zwinderman AH; Majoor CJ; Bonta PI; Ravanetti L; Sterk PJ; Lutter R
Am J Respir Crit Care Med; 2019 Feb; 199(4):508-517. PubMed ID: 30192638
[TBL] [Abstract][Full Text] [Related]
37. Interleukin-25 and eosinophils progenitor cell mobilization in allergic asthma.
Tang W; Smith SG; Du W; Gugilla A; Du J; Oliveria JP; Howie K; Salter BM; Gauvreau GM; O'Byrne PM; Sehmi R
Clin Transl Allergy; 2018; 8():5. PubMed ID: 29456832
[TBL] [Abstract][Full Text] [Related]
38. Sputum autoantibodies in patients with severe eosinophilic asthma.
Mukherjee M; Bulir DC; Radford K; Kjarsgaard M; Huang CM; Jacobsen EA; Ochkur SI; Catuneanu A; Lamothe-Kipnes H; Mahony J; Lee JJ; Lacy P; Nair PK
J Allergy Clin Immunol; 2018 Apr; 141(4):1269-1279. PubMed ID: 28751233
[TBL] [Abstract][Full Text] [Related]
39. Effects of Anti-T2 Biologic Treatment on Lung Ventilation Evaluated by MRI in Adults With Prednisone-Dependent Asthma.
Svenningsen S; Eddy RL; Kjarsgaard M; Parraga G; Nair P
Chest; 2020 Oct; 158(4):1350-1360. PubMed ID: 32428511
[TBL] [Abstract][Full Text] [Related]
40. A halotyrosine antibody that detects increased protein modifications in asthma patients.
Jin H; Hallstrand TS; Daly DS; Matzke MM; Nair P; Bigelow DJ; Pounds JG; Zangar RC
J Immunol Methods; 2014 Jan; 403(1-2):17-25. PubMed ID: 24295867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
